

Emtricitabine + tenofovir alafenamide

REJECTED

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.
The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

General description

| | |
|--------------------|---|
| INN | Emtricitabine + tenofovir alafenamide |
| ATC codes | J05AR17 |
| Medicine type | Chemical agent |
| EML status history | Application rejected in 2017 (TRS 1006) for Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified |
| Wikipedia | Emtricitabine + tenofovir alafenamide ↗ |
| DrugBank | Emtricitabine ↗, Tenofovir alafenamide ↗ |

Recommendations

Section Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

